Patients and Methods
Introduction ▼
Diabetes is one of the major health problems worldwide. According to the results of China National Diabetes and Metabolic Disorders Study, the prevalence of total diabetes in China were 9.7 % [ 1 ] . In patients with diabetes, cardiovascular and cerebrovascular disease is the major cause of morbidity and mortality. Current medical evidence suggested that lipid-lowering medications could lead to a signifi cant reduction in major cardiovascular events in patients with diabetes. As one of lipid-lowering medications, statin has been considered to play a very important role in reducing the mortality of coronary artery disease [ 2 -5 ] . However, with regard to the primary prevention, confl icting evidence has resulted in controversy regarding the use of statins in patients with diabetes without established cardiovascular disease [ 6 , 7 ] . Therefore, the present meta-analysis was designed to clarify the effi cacy of statin on primary prevention of cardiovascular and cerebro-Results: A total of 1 376 MACCE occurred during follow-up, with 9.54 % (605 patients) in the statin therapy group and 12.10 % (771 patients) in control group. Statin therapy was associated with a signifi cant reduction in the incidence of MACCE (0.79, 95 %CI 0.66-0.95; P = 0.01). Meanwhile, the risk of stroke and coronary revascularization were reduced 29 and 26 % in statin therapy group. However, there was no statistical diff erence of all-cause mortality between statinand control-therapy group (3.73 vs. 4.65 %, P = 0.13). Conclusions: For primary prevention in patients with diabetes without established cardiovascular disease, statin therapy could reduce the cardiovascular and cerebrovascular events, but not all-cause mortality. 
Study identifi cation and extraction
Trials that met the following criteria were included: (1) Randomized controlled trials; (2) patients with diabetes without established cardiovascular disease; (3) there was a direct comparison between statins group and control group for primary prevention of vascular events; (4) outcomes including any of major cardiovascular and cerebrovascular events, such as fatal or non-fatal myocardial infarction, cardiac sudden death, coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting), angina, all-cause mortality and fatal or non-fatal stroke; (5) follow-up duration at least 12 months. The following information was collected: (1) fi rst author's names; (2) trial names; (3) the year of publication or presentation; (4) target population of trials (5) total sample size and subgroup sample size; (5) history of hypertension, smoking, body mass index and basic HbA1c (6) baseline cholesterol and triglycerides and changes; (7) the type and daily dosage of the statin therapy; (8) primary and secondary outcomes of the studies; (9) the mean period of follow-up.
Study outcome
The outcomes of interest were major adverse cardiovascular and cerebrovascular events (MACCE), including fatal or non-fatal myocardial infarction (MI), cardiac sudden death, indentifi ed coronary heart disease (CHD), coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting), angina pectoris and fatal or non-fatal stroke. All-cause mortality was also evaluated across the trials.
Statistical analysis
The meta-analysis was performed according to the recommendations from the Cochrane Collaboration with Review Manager 5.0. The eff ect of statins on the occurrence of MACCE or each event was presented as odds ratio (OR) with 95 % confi dence intervals (CI) using a fi xed-eff ects model. Alternatively, randomeff ects meta-analyses were performed when between-study variability existed. Heterogeneity was quantifi ed using the I 2 statistic ( I 2 represents the percentage of variability due to between-study variability.) We regarded I 2 of less than 25 %, 25-50 %, and greater than 50 % as low, moderate and high amounts of heterogeneity, respectively. Publication bias was evaluated using the funnel plot. Results were considered statistically signifi cant if P < 0.05.
Results

▼ Eligible studies and baseline characteristics
The electronic database search identifi ed 7 studies, which fulfi lled our eligibility criteria. The included studies enrolled a total of 12 711 participants (6 340 patients in statin-therapy group and 6 371 in control-therapy group). The baseline characteristics of each study [ 6 -12 ] were summarized in • ▶ Table 1 . We found that basic cholesterol levels were mildly elevated in the target patients, while basic triglycerides levels were normal.
Eff ect of statin therapy on MACCE
There were 7 studies reported the MACCE data after at least 3.2 years follow-up. A total of 12 711 patients were enrolled, including 6 340 patients in statin-therapy group and 6 371 in controltherapy group. A total of 1 376 MACCE occurred during follow-up, with 9.54 % (605 patients) in the statin therapy group and 12.10 % (771 patients) in control group. Statin therapy was associated with a signifi cant reduction in the incidence of MACCE (0.79, 95 %CI 0.66-0.95; P = 0.01; • ▶ Fig. 1 ).
Eff ect of statin therapy on all-cause mortality
With regard to the eff ect of statin on the all-cause mortality, there were 272 events among 6 489 patients in 3 trials. The allcause mortality was 3.73 % among statin therapy group, which was similar to the rate (4.65 %) among control group ( P = 0.13, • ▶ Fig. 2 ).
Eff ect of statin therapy on stroke
A total of 216 stroke events occurred in 4 studies, including fatal and non-fatal stroke. There were 90 cases (2.0 %) of stroke among statin therapy patients and 126 cases (2.79 %) among controltherapy patients ( • ▶ Fig. 3 ). The risk of stroke was reduced 29 % in statin therapy group (0.71, 95 %CI 0.54-0.94; P = 0.01) by the fi xed eff ects model, with no signifi cant heterogeneity ( P = 0.71)
Eff ect of statin therapy on coronary revascularization
Patients with diabetes, treated with statin or placebo, diff ered signifi cantly with respect to the risk of coronary revascularization (including percutaneous coronary intervention or coronary artery bypass grafting) in 3 trials. There were 81 cases (2.22 %) of coronary revascularization in statin group and 107 cases (2.95 %) in control group (0.74, 95 %CI 0.55-1.00; P = 0.05 and P = 0.30 for heterogeneity), shown in • ▶ Fig. 4 . Fig. 1 Odds ratios of major adverse cardiovascular and cerebrovascular events associated with statin vs. control therapy in patients with diabetes. Fig. 2 Odds ratios of all-cause mortality associated with statin vs. control therapy in patients with diabetes. 
Publication bias
Funnel plots were performed for all outcomes, including the incidence of MACCE, mortality, stroke and coronary revascularization were symmetrically displayed.
Discussion ▼
The present meta-analysis suggests that for primary prevention in patients with diabetes without established cardiovascular disease, statin therapy could reduce the cardiovascular and cerebrovascular events, but not all-cause mortality.
As one of confi rmed risk factors, diabetes mellitus is not only associated with a 2-to 4-fold increase in the risk of coronary artery disease (CAD), but also related to its severity [ 13 , 14 ] . In 2001, the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) report elevated diabetes from a CHD risk factor to a CHD risk equivalent. Meanwhile, ATP III also recommended the initiation of pharmacotherapy for patients with a CHD risk equivalent (the presence of diabetes, peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease or multiple risk factors with a 10-year Framingham risk of CHD of > 20 %) and an LDL-C concentration of ≥ 130 mg/dl [ 15 ] . Current medical evidence [ 2 , 3 ] suggested that lipid-lowering medications could lead to a signifi cant reduction in major cardiovascular events in patients with diabetes. As one of lipidlowering medications, statin has been considered to play a very important role in reducing the mortality of coronary artery disease [ 4 , 16 , 17 ] . However, with regard to the primary prevention, confl icting evidence has resulted in controversy regarding the use of statins in patients with diabetes without established cardiovascular disease. A signifi cant 37 % reduction in risk of cardiovascular events was observed with atorvastatin in CARDS, and a signifi cant 33 % reduction in risk of cardiovascular events was observed in HPS. However, in the study of ASCOT-LLA [ 7 ] , a nonsignifi cant 16 % reduction in coronary heart disease death and nonfatal myocardial infarction was observed with 10 mg of atorvastatin in patients with diabetes. Moreover, in the study of ASPEN [ 6 ] , 10.4 % of atorvastatin-treated patients without prior MI or interventional procedure experienced a primary cardiovascular end point, which was similar to the incidence in placebo-treated subjects (10.8 %, P > 0.05). Researchers did not fi nd a signifi cant reduction in the primary composite end point comparing 10 mg of atorvastatin with placebo (13.7 and 15.0 %, P > 0.05). When compared with CARDS, primary prevention patients in ASPEN were younger and less hypertensive and included less smokers and men. The low risk of CHD in primary prevention patients with diabetes may account for the unpromising result. Therefore, we designed this meta-analysis to clarify the effi cacy of statin on primary prevention of cardiovascular and cerebrovascular events in patients with diabetes without established cardiovascular diseases. A total of 7 trials were ultimately included in this meta-analysis, involving 12 711 patients with diabetes without established cardiovascular diseases (6 340 randomized to the statin-therapy group and 6 371 randomized to the control-therapy group). After analysis the incidence of total MACCE, we found that statin therapy reduced 21 % incidence of MACCE, which benefi ted the patients with diabetes for the primary prevention. In addition, statin therapy also reduced the risk of stroke (29 %) and coronary revascularization (26 %) in patients with diabetes, although the change of all-cause mortality did not reach the statistical diff erence. The results indicated that statin therapy in low risk patients, even without established coronary heart disease, myocardial infarction and stroke, did benefi t for the primary prevention.
As regards with primary prevention, it should be taken into account for cost performance. It had been confi rmed in previous studies that diff erent type and diff erent dosage of statin had different effi cacy on the level of cholesterol and risk reduction of cardiovascular events [ 18 , 19 ] . 10 mg atorvastatin could decrease the serum level of LDL-C by 30-40 %. In order to achieve the similar eff ects, lovastatin should increase to 40-80 mg, while simvastatin was 20 mg [ 20 ] . However, it was interesting that we did not fi nd more benefi t from the usage of higher dosage or stronger effi cacy of statins in our meta-analysis. , the dosage and types of statin were quite diff erent. In the study of MEGA, the statin usage was 10-20 mg pravastatin daily, which reduced the level of LDL-C by 18 %, while 10 mg atorvastatin reduced the serum level of LDL-C by 33 % in the study of CARDS. These data implied us that higher dosage of statin or greater reduction of LDL-C should not be the sole consideration of various factors in primary prevention for patients with diabetes. The benefi t might be off set by the side eff ects of large dosage of diff erent statins. In the present metaanalysis, we also investigated whether diff erent type of statin had diff erent effi cacy on reduction in the incidence of MACCE. We conduct a sub-analysis by including 3 trials (CARDS, ASCOT-LLA and ASPEN), which atorvastatin was assigned in the studies, and found that the MACCE (0.78, 95 %CI 0.63-0.95; P = 0.01) was similar to the MACCE (0.79, 95 %CI 0.66-0.95; P = 0.01) when all the statin trials were included. These data implied that for the primary prevention, the benefi ts of statin therapy are likely to be similar. Our study had several limitations. First, this meta-analysis was limited by the lack of complete availability of relevant data. Data of all-cause mortality, cardiac mortality, stroke and myocardial infarction were not available in some included studies. Therefore, there may be reporting bias in these outcomes. Especially, all-cause mortality was only reported in 3 trials which suggested this analysis might be underpowered on all-cause mortality. Second, the usage of other medicine, such as ACEI/ARB, beta-blocker and aspirin, were not unclear. It has been clearly demonstrated that these medicine might infl uence the incidence of cardiovascular events. Third, longer follow-up period was needed for the primary prevention, which would be more meaningful for guiding further therapeutic plan.
Conclusions ▼
For primary prevention in patients with diabetes without established cardiovascular disease, statin therapy could reduce the cardiovascular and cerebrovascular events, but not all-cause mortality.
